Back to results
US 2020/0046700 A1Published application
Focal adhesion kinase inhibitor as a therapeutic agent in diabetes
AssigneeUniversity of Pittsburgh—Of the Commonwealth System of Higher Education
InventorsFarzad Esni, Jing Hu
Life of this patent
Estimating the term…
Abstract
It is disclosed herein that a FAK inhibitor induces conversion of acinar cells into beta cells. Methods are provided for increasing beta cell proliferation by administering an effective amount of a FAK inhibitor to a subject in need thereof. Methods are also provided for treating a subject with diabetes or at risk of developing diabetes, comprising administering to the subject a therapeutically effective amount of a FAK inhibitor.
Claims16
A method for treating a subject with diabetes, pre-diabetes, or a predisposition for diabetes, comprising:
- administering to the subject a therapeutically effective amount of a focal adhesion kinase (FAK) inhibitor, thereby treating the diabetes, pre-diabetes, or predisposition for diabetes.
(canceled)
Dependencies are inferred from the claim text.